Immunizations with Pneumococcal Surface Protein A and Pneumolysin Are Protective against Pneumonia in a Murine Model of Pulmonary Infection withStreptococcus pneumoniae
Citations Over TimeTop 10% of 2003 papers
Abstract
Intranasal infection of mice with certain strains of capsular group 19 Streptococcus pneumoniae can result in focal pneumonia in the absence of bacteremia. Using this model of murine pneumonia, we demonstrated that immunization with recombinant forms of either pneumococcal surface protein A (PspA) or PdB (a genetically detoxified derivative of pneumolysin) elicited significant protection against focal pulmonary infection. This may be the first demonstration that a proposed vaccine antigen can protect against pneumococcal pneumonia. The best protection was obtained by immunizing mice with a mixture of PspA and PdB, indicating that the protection elicited by these antigens can complement each other. This result is in agreement with previous studies that used pneumococcal sepsis and nasal colonization models and demonstrate that the best protein vaccines for prevention of infection may be those that include more than one protection-eliciting pneumococcal protein.
Related Papers
- → Toxicity of pneumolysin to pulmonary alveolar epithelial cells(1993)107 cited
- → Apigenin protects mice from pneumococcal pneumonia by inhibiting the cytolytic activity of pneumolysin(2016)31 cited
- Demonstration of pneumolysin antibodies in circulating immune complexes - a new diagnoxtic method for pneumococcal pneumonia.(1990)
- Pneumococcal vaccine: a second look. Solution for SC or IM injection: pneumococcal vaccine.(1998)
- [Proteins of Streptococcus pneumoniae: perspectives for development of pneumococcal vaccine].(2011)